Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MRM-OT1
- Development stage
- Preclinical
- Lead developer
- Zylem Biosciences
- Modality
- Peptides
- Administration
- Ophthalmic
01
Overview
MRM-OT1 is a preclinical-stage high-density lipoprotein (HDL) mimic being developed by Zylem Biosciences for the treatment of various ocular surface conditions. The drug acts as an agonist of the Scavenger Receptor Class B Type 1 (SR-B1), a receptor involved in lipid transport and anti-inflammatory signaling. By mimicking the structure and function of natural HDL, MRM-OT1 aims to promote corneal wound healing and reduce inflammation. Its primary indications include dry eye disease, atopic keratoconjunctivitis, bacterial keratitis, and chemical or thermal eye injuries, as well as supporting post-surgical recovery and contact lens wear comfort.
02
Targets
SCARB1 (Scavenger receptor class B member 1)
Beyond the preview
Go deeper on MRM-OT1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MRM-OT1.